ReviewThe global burden of group A streptococcal diseases
Introduction
Group A streptococcus (GAS) causes a broad spectrum of diseases, all of which are most common in settings of poverty, where systems for collection of accurate disease burden data are usually absent. Therefore, any attempt to measure the global burden of GAS diseases will be hindered by the breadth of information that is needed and the paucity of reliable information from countries where these diseases are most important. There has been no recent attempt to collate such information. The only GAS disease for which global disease burden estimates have been made is rheumatic heart disease.1, 2
We aim to use existing data sources to estimate the global burden of GAS diseases, and to identify the most critical deficiencies in GAS disease burden data. The full report of this project is available at http://www.who.int/child-adolescent-health/publications/CHILD_HEALTH/DP/Topic_2/paper_1.htm. Here, we present a summary of the major findings.
Section snippets
Methods
We did systematic reviews, aiming to include only recent, population-based data where possible. For severe GAS diseases (eg, acute rheumatic fever, rheumatic heart disease, acute post-streptococcal glomerulonephritis, and invasive disease) we searched for publications after Jan 1, 1985. For streptococcal skin and upper respiratory infections, we extended the literature search back to Jan 1, 1980 to include more studies. We also reviewed the proceedings of the 3-yearly meetings of the Lancefield
Prevalence of rheumatic heart disease
We found 57 studies that met our inclusion criteria. There was only one population-based study for each of eastern Europe, China, and the established market economies. Sufficient data were available to include only echocardiographic studies from all regions except eastern Europe, Asia other, and China. The highest calculated regional prevalences were found in sub-Saharan Africa (5·7 cases per 1000), the Pacific and indigenous Australia and New Zealand (3·5 cases per 1000), and south central
Discussion
These estimates suggest that, on a global scale, GAS is an important cause of morbidity and mortality, mainly in less developed countries. For example, the minimum estimate of over 500 000 deaths per year places GAS among the major human pathogens, only exceeded by HIV, Mycobacterium tuberculosis, Plasmodium falciparum, and Streptococcus pneumoniae, and probably comparable to rotavirus, measles, Haemophilus influenzae type b, and hepatitis B (figure 3).60 Group A streptococcus causes more
References (61)
- et al.
Mortality due to acute rheumatic fever and rheumatic heart disease in the Northern Territory: a preventable cause of death in aboriginal people
Aust N Z J Public Health
(1999) - et al.
Brain infarct causes under the age of fifty: a comparison between an east-Asian (Thai) and a western (Dutch) hospital series
Clin Neurol Neurosurg
(1993) - et al.
Incidence of biopsy-proven primary glomerulonephritis in an Italian province
Am J Kidney Dis
(1996) - et al.
Epidemiology of primary glomerular diseases in a French region. Variations according to period and age
Kidney Int
(1994) - et al.
Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea
Acta Trop
(2000) - et al.
World Health Report 2002. Reducing risks, promoting healthy life
(2002)- et al.
Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population?
Epidemiol Infect
(2000) Central Australian rheumatic heart disease control program, Commonwealth Report, November 2002. Alice Springs
(2002)- et al.
Rheumatic heart disease in India
J R Soc Health
(1995)
Prevalence of cardiovascular diseases in rural area of Hmawbi and urban Yangon city
Asia Pacific J Public Health
Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals
Pediatrics
Rheumatic fever and streptococcal infection
Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory
Med J Aust
The epidemiology of rheumatic fever
Mortality and social class in Maori and nonMaori New Zealand men: changes between 1975-7 and 1985-7
N Z Med J
Cardiac mortality in Alaska's indigenous and non-Native residents
Int J Epidemiol
The natural history of rheumatic fever
Rheumatic heart disease: Prognosis
The natural history of rheumatic fever and rheumatic heart disease in the Orient
Jpn Heart J
Ten-year follow up of a cohort with rheumatic heart disease (RHD)
Aust N Z J Med
Acute poststreptococcal glomerulonephritis
Bacteremia among children admitted to a rural hospital in Kenya
N Engl J Med
The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study
JAMA
Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection
Epidemiol Infect
Invasive group A streptococcal disease in North Queensland (1996-2001)
Indian J Med Res
Infective endocarditis in a tertiary-care hospital in southern Israel
Public Health Rev
Heart disease and stroke statistics—2003 update
Stroke in Saudi Arabian young adults: a study of 120 cases
Acta Neurol Scand
Cited by (2192)
Systematic review and meta-analysis of the accuracy of McIsaac and Centor score in patients presenting to secondary care with pharyngitis
2024, Clinical Microbiology and InfectionThe associations between invasive group A streptococcal disease and infection with influenza, varicella, or hepatitis C viruses: A data linkage study, Victoria, Australia
2024, International Journal of Infectious DiseasesMolecular characterization of the interaction between human IgG and the M-related proteins from Streptococcus pyogenes
2024, Journal of Biological ChemistrySystematic identification and repurposing of FDA-approved drugs as antibacterial agents against Streptococcus pyogenes: In silico and in vitro studies
2024, International Journal of Biological Macromolecules